Enrico Martin

82 Chapter 4 References 1. Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res . 2013;33(6):2597-2604. 2. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg . 2009;249(6):1014-1022. doi:10.1097/ SLA.0b013e3181a77e9a 3. Stucky C-CH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol . 2012;19(3):878-885. doi:10.1245/s10434-011-1978-7 4. Martin E, Muskens IS, Coert JH, Smith TR, Broekman MLD. Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis and review of the literature. Neuro-Oncology Pract . July 2018. doi:10.1093/nop/npy025 5. Bates JE, Peterson CR, Dhakal S, Giampoli EJ, Constine LS. Malignant Peripheral Nerve Sheath Tumors ( MPNST ): A SEER Analysis of Incidence Across the Age Spectrum and Therapeutic Interventions in the Pediatric Population. 2014;(August):1955-1960. doi:10.1002/pbc 6. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol . 2005;23(33):8422-8430. doi:10.1200/ JCO.2005.01.4886 7. Ferner RE, Lucas JD, O’Doherty MJ, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18) FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg PS YCHI ATRY . 2000;68 (3):353 -357. doi:10.1136/jnnp.68.3.353 8. Broski SM, Johnson GB, Howe BM, et al. Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiol . 2016;45(8):1097-1105. doi:10.1007/ s00256-016-2394-7 9. Brooks JS, Freeman M, Enterline HT. Malignant “Triton” tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer . 1985;55(11):2543-2549. 10. Li G, Liu C, Liu Y, et al. Analysis of clinical features and prognosis of malignant triton tumor: A report of two cases and literature review. Oncol Lett . 2015;10(6):3551-3556. doi:10.3892/ol.2015.3762 11. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer . 2016;56:77-84. doi:10.1016/j.ejca.2015.12.015 12. Pratt CB, Maurer HM, Gieser P, et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol . 1998;30(4):201-209. 13. Spunt SL, Hill DA, Motosue AM, et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol . 2002;20(15):3225- 3235. doi:10.1200/JCO.2002.06.066 14. Ferrari A, Casanova M, Collini P, et al. Adult- type soft tissue sarcomas in pediatric- age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol . 2005;23(18):4021-4030. doi:10.1200/ JCO.2005.02.053